Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Department of PET Center, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
J Urol. 2023 Dec;210(6):845-855. doi: 10.1097/JU.0000000000003680. Epub 2023 Aug 30.
Radical prostatectomy is one of the primary treatments for localized clinically significant prostate cancer. Generally, its application is based on prior biopsy. PSMA (prostate-specific membrane antigen)-PET (positron emission tomography) is considered promising in biopsy-free radical prostatectomy. The expression of PSMA in benign prostatic hyperplasia tissue and corresponding positive reaction are crucial concerns for a no-biopsy strategy. Currently, no study has explored the benign prostatic hyperplasia-related false-positive of PSMA-PET in the detection of prostate cancer. Furthermore, the influence of maximum standardized uptake value and Prostate Imaging Reporting & Data System on biopsy-free radical prostatectomy is also poorly characterized.
A retrospective study was conducted on patients who received PSMA-PET because of clinical suspicion of prostate cancer and were confirmed to have benign prostatic hyperplasia or prostate cancer. The receiver operating characteristic curve was generated for maximum standardized uptake value. Results of interest were the false-positive rate of PSMA-PET and the efficacy of maximum standardized uptake value or multiparametric MRI in excluding false-positives.
The benign prostatic hyperplasia-related false-positive rate of PSMA-PET in detecting prostate cancer was 30%. Maximum standardized uptake value could effectively exclude benign prostatic hyperplasia and Grade Group 1 patients with an area under the curve of 0.86; the optimal maximum standardized uptake value cutoff value with 100% specificity was 15, with a sensitivity of 41%. Notably, the sensitivity and specificity of stringent PET score and Prostate Imaging Reporting & Data System criteria (both ≥4) in diagnosing clinically significant prostate cancer were 49% and 100%, respectively.
Our findings revealed benign prostatic hyperplasia-related false-positive rate of PSMA-PET and provided a preliminary reference in biopsy-free radical prostatectomy.
根治性前列腺切除术是治疗局限性临床显著前列腺癌的主要方法之一。通常,其应用基于先前的活检。PSMA(前列腺特异性膜抗原)-PET(正电子发射断层扫描)被认为在无活检根治性前列腺切除术中具有很大的应用前景。PSMA 在良性前列腺增生组织中的表达和相应的阳性反应是无活检策略的关键关注点。目前,尚无研究探讨 PSMA-PET 在前列腺癌检测中对良性前列腺增生的假阳性。此外,最大标准化摄取值和前列腺影像报告和数据系统对无活检根治性前列腺切除术的影响也尚未得到很好的描述。
对因临床怀疑前列腺癌而接受 PSMA-PET 检查且证实为良性前列腺增生或前列腺癌的患者进行回顾性研究。生成最大标准化摄取值的受试者工作特征曲线。感兴趣的结果是 PSMA-PET 的假阳性率以及最大标准化摄取值或多参数 MRI 在排除假阳性方面的效果。
PSMA-PET 检测前列腺癌的良性前列腺增生相关假阳性率为 30%。最大标准化摄取值可以有效地排除良性前列腺增生和分级组 1 患者,曲线下面积为 0.86;具有 100%特异性的最佳最大标准化摄取值截断值为 15,灵敏度为 41%。值得注意的是,严格 PET 评分和前列腺影像报告和数据系统标准(均≥4)诊断临床显著前列腺癌的灵敏度和特异性分别为 49%和 100%。
我们的研究结果揭示了 PSMA-PET 的良性前列腺增生相关假阳性率,并为无活检根治性前列腺切除术提供了初步参考。